clinical trial · NCT05312970
Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS)
Varicose VeinsVarithena®FDA-approved Endothermal Ablation (ETA) systems
brief summary
The purpose of this study is to observe insights into the benefits of Varithena compared to Endothermal Ablation (ETA) in the treatment of the great saphenous vein.
started
Feb 10, 2023
primary completion
Apr 4, 2024
completion
Apr 4, 2024
last updated
Mar 20, 2026
detailed description
To collect comparative evidence on patient reported outcomes of Varithena compared to ETA when used to treat the incompetent great saphenous vein (GSV). ETA will include either radiofrequency ablation or endovenous laser ablation according to the site's standard practice. To provide long term (1-year, 2-year, and 3-year) outcomes.
official title
A Phase 4 Randomized Trial Comparing Varithena to Endothermal Ablation for the Treatment of the Great Saphenous Vein
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol